Drug Profile
Anti-TF monoclonal antibody - NEMOD
Alternative Names: KaroMab™Latest Information Update: 15 Feb 2008
Price :
$50
*
At a glance
- Originator NEMOD Biotherapeutics [CEASED]
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Apr 2006 No development reported - Preclinical for Cancer in Germany (Injection)
- 25 Aug 2004 KaroMab™ is available for licensing http://www.nemod.com)
- 26 Jun 2003 Preclinical trials in Cancer in Germany (unspecified route)